Search Within

Hani Hassoun

Formats
  1. Meeting Abstract (232)
  2. Journal Article (90)
  3. Research Letter (9)
  4. Correspondence (4)
  5. Book Section (2)
  6. Review (2)
Groups
  1. Center for Hematologic Malignancies (339)
  2. Department of Medicine (339)
  3. Hematologic Malignancies, Division of (339)
  4. Myeloma (339)
  5. Survivorship Research (253)
  6. Bone Marrow Transplant (241)

More Groups

People
  1. Heather Landau (224)
  2. Sergio Giralt (205)
  3. Alexander Lesokhin (202)
  4. David Chung (166)
  5. Neha Korde (166)
  6. Sham Mailankody (163)

More People

Years
  1. 2025 (7)
  2. 2024 (35)
  3. 2023 (37)
  4. 2022 (36)
  5. 2021 (21)
  6. 2020 (28)

More Years

Publications
  1. Blood (133)
  2. Clinical Lymphoma, Myeloma and Leukemia (51)
  3. Journal of Clinical Oncology (27)
  4. Biology of Blood and Marrow Transplantation (19)
  5. Leukemia and Lymphoma (14)
  6. American Journal of Hematology (10)

More Publications

Publishers
  1. American Society of Hematology (141)
  2. Elsevier Inc. (74)
  3. American Society of Clinical Oncology (27)
  4. Nature Publishing Group (24)
  5. Taylor & Francis Group (21)
  6. John Wiley & Sons, Inc. (10)

More Publishers

Results (339)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Efficacy and risk factors analysis of upfront autologous stem cell mobilization using plerixafor and granulocyte-colony stimulating factor (GCSF) in patients with multiple myeloma
    Meeting Abstract

    Ogunniyi, A.; Rodriguez, M.; Devlin, S. M.; Adel, N. G.; Landau, H.; Chung, D. J.; Lendvai, N.; Lesokhin, A. M.; Landgren, O.; Giralt, S. A.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • Increased bone marrow plasma cells at diagnosis predicts overall mortality in AL amyloidosis patients undergoing risk-adapted stem cell transplant
    Meeting Abstract

    Landry, C. A.; Smith, M.; Chou, J. F.; Devlin, S. M.; Hassoun, H.; Bello, C.; Landgren, O.; Giralt, S.; Comenzo, R. L.; Landau, H.
    Blood (2014)

    Fulltext@MSK | Save
  • Greater total dose and duration of treatment with bortezomib are associated with higher incidence of chalazion and other ocular side effects
    Meeting Abstract

    Ganesh, K.; Batlevi, C.; Zhang, Z. G.; Hassoun, H.; Lendvai, N.; Landau, H.; Moskowitz, C. H.; Caron, P.; Motzer, R.; Giralt, S. A.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • Analysis of VDT-PACE utilization in multiple myeloma patients treated at MSKCC for relapsed disease or cytoreduction and stem cell mobilization after initial induction therapy
    Meeting Abstract

    Beyer, K.; Rosner, S.; Woo, K. M.; Devlin, S. M.; Landau, H.; Hassoun, H.; Lendvai, N.; Chung, D. J.; Adel, N. G.; Puto, M.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • Upfront plerixafor plus G-CSF versus cyclophosphamide plus G-CSF for autologous stem cell mobilization in multiple myeloma patients: An update on cost analysis study at Memorial Sloan Kettering Cancer Center
    Meeting Abstract

    Afifi, S.; Adel, N. G.; Duck, E.; Devlin, S. M.; Landau, H.; Lendvai, N.; Lesokhin, A. M.; Chung, D. J.; Landgren, O.; Giralt, S. A.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • Successful perioperative use of prothrombin complex concentrate in the treatment of acquired factor X deficiency in the setting of systemic light-chain (AL) amyloidosis
    Journal Article

    Litvak, A.; Kumar, A.; Wong, R. J.; Smith, L.; Hassoun, H.; Soff, G.
    American Journal of Hematology (2014)

    Fulltext@MSK | Save
  • Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis
    Journal Article

    Reece, D. E.; Hegenbart, U.; Sanchorawala, V.; Merlini, G.; Palladini, G.; BladeĢ, J.; Fermand, J. P.; Hassoun, H.; Heffner, L.; Kukreti, V.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • Plasma cell disorders
    Book Section

    Burke, P. W.; Hassoun, H.; Palomba, M. L.; Kumar, A.; Landau, H. J.
    In Drilon, A. E.; Postow, M. A.; Krug, L. M. (Eds.) Pocket Oncology (2014)

    Fulltext@MSK | Save
  • A phase 2 single-center study of carfilzomib 56 mg/m2 with or without low-dose dexamethasone in relapsed multiple myeloma
    Journal Article

    Lendvai, N.; Hilden, P.; Devlin, S.; Landau, H.; Hassoun, H.; Lesokhin, A. M.; Tsakos, I.; Redling, K.; Koehne, G.; Chung, D. J.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • A case of protothecosis in a patient with multiple myeloma
    Journal Article

    Figueroa, C. J.; Camp, B. J.; Varghese, G. I.; Miranda, E.; Querfeld, C.; Hassoun, H.; Kamboj, M.; Pulitzer, M. P.
    Journal of Cutaneous Pathology (2014)

    Fulltext@MSK | Save